Your session is about to expire
← Back to Search
TGR-1202 + Ruxolitinib for Polycythemia Vera
Study Summary
This trial is testing a new drug to treat myeloproliferative neoplasms (a type of blood cancer) when used with another existing drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had a bone marrow biopsy within the last 4 weeks to check my fibrosis score.I am able to care for myself and perform daily activities.I have recovered from previous cancer treatment side effects, except for hair loss and certain blood conditions.My organ functions are within normal ranges according to recent tests.I haven't had any cancer except for skin, prostate, cervical, or DCIS in the last 2 years.I haven't had a stroke, heart attack, or severe heart rhythm problems in the last 6 months.I have had a recent stem cell transplant or have active graft-versus-host disease.I have not had recent major surgery, chemotherapy, or immunotherapy.I can follow the study's requirements without any issues.I have a confirmed diagnosis of a specific type of bone marrow disorder and am at an intermediate or high risk.I have a history of HIV or active hepatitis A, B, or C.I am currently on immunosuppressive therapy or have recently had radiotherapy.I have been diagnosed with MF, PV, CMML, aCML, RARS-T, or MDS/MPN-U and can get ruxolitinib.I have not taken any experimental drugs or specific inhibitors recently.I haven't taken specific drugs recently.
- Group 1: Escalation and expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there various sites executing this research in the US and Canada?
"Presently, this clinical trial is available at 5 distinct sites located in Nashville, Aurora and Phoenix among others. To mitigate the travel burden associated with enrollment, it may be best to select a site that is closest to you."
Could you elucidate the potential risks associated with TGR-1202?
"With limited data to suggest both safety and efficacy, TGR-1202 was given an assessment of 1."
In what conditions has TGR-1202 demonstrated efficacy?
"TGR-1202 has been proven to help patients manage lymphoma, polycythemia vera, and polycythemia."
Are there any openings remaining for participants in this research?
"This medical trial has concluded its recruitment process, having last been updated on June 20th 2022. However, there are presently 153 clinical trials recruiting patients with polycythemia vera and 108 trails looking for participants receiving TGR-1202 treatments."
What is the upper limit of participants for this research endeavor?
"This research project is not presently accepting participants. Although the trial was initially posted in July 2015, it has since been updated as of June 2022. For those seeking alternative studies, 153 trials for polycythemia vera and 108 studies concerning TGR-1202 are currently recruiting patients."
Are there any existing reports associated with TGR-1202?
"TGR-1202 was first investigated at the NIH Clinical Center in 2002 and since then 100 trials have been completed. At present, there are 108 active experiments taking place across multiple locations with a concentration of research occurring in Nashville, Tennessee."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger